levofloxacin has been researched along with glycyrrhetinic acid in 2 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (glycyrrhetinic acid) | Trials (glycyrrhetinic acid) | Recent Studies (post-2010) (glycyrrhetinic acid) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 102 | 0 | 67 |
| Protein | Taxonomy | levofloxacin (IC50) | glycyrrhetinic acid (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 4.9 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Rattus norvegicus (Norway rat) | 0.09 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Homo sapiens (human) | 0.1853 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 1 | Mus musculus (house mouse) | 0.0124 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 2 | Rattus norvegicus (Norway rat) | 0.36 | |
| Corticosteroid 11-beta-dehydrogenase isozyme 2 | Homo sapiens (human) | 0.1035 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 9.6 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 0.5495 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.5248 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
2 other study(ies) available for levofloxacin and glycyrrhetinic acid
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |